Castle Biosciences Inc [CSTL] stock is trading at $23.46, up 5.30%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CSTL shares have gain 17.48% over the last week, with a monthly amount glided 45.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Castle Biosciences Inc [NASDAQ: CSTL] stock has seen the most recent analyst activity on December 14, 2023, when Guggenheim initiated its Buy rating and assigned the stock a price target of $25. Previously, Scotiabank started tracking the stock with Sector Outperform rating on January 05, 2023, and set its price target to $54. On January 07, 2022, Stephens initiated with a Overweight rating and assigned a price target of $59 on the stock. Lake Street started tracking the stock assigning a Buy rating and suggested a price target of $94 on April 30, 2021. KeyBanc Capital Markets initiated its recommendation with a Overweight and recommended $70 as its price target on November 10, 2020. Canaccord Genuity reiterated a Buy rating for this stock on December 27, 2019, and upped its price target to $35. In a note dated August 19, 2019, SVB Leerink initiated an Outperform rating and provided a target price of $28 on this stock.
Castle Biosciences Inc [CSTL] stock has fluctuated between $14.59 and $35.84 over the past year. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Castle Biosciences Inc [NASDAQ: CSTL] shares were valued at $23.46 at the most recent close of the market. An investor can expect a potential return of 27.88% based on the average CSTL price forecast.
Analyzing the CSTL fundamentals
Castle Biosciences Inc [NASDAQ:CSTL] reported sales of 346.27M for the trailing twelve months, which represents a drop of -0.94%. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.02 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.41 points at the first support level, and at 21.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.10, and for the 2nd resistance point, it is at 24.74.
Ratios To Look Out For
For context, Castle Biosciences Inc’s Current Ratio is 6.85. In addition, the Quick Ratio stands at 6.69 and the Cash Ratio stands at 1.62. Considering the valuation of this stock, the price to sales ratio is 1.97, the price to book ratio is 1.49.
Transactions by insiders
Recent insider trading involved Kristen M. Oelschlager, Officer, that happened on Aug 27 ’25 when 18007.0 shares were purchased. Officer, Kristen M. Oelschlager completed a deal on Aug 27 ’25 to buy 25355.0 shares. Meanwhile, Pres. & Chief Exec. Officer MAETZOLD DEREK J sold 1339.0 shares on Aug 15 ’25.
